thx for post, good to see Lanza's name attached to this developing technology. I do think it is probable that the company Platelet BioGenesis will be the company involved in the 2017 trials since two of their people in the paper are from there and have a very advanced platelet bioreactor IP. Here is PB's 'about':
We have developed a microfluidic-based bioreactor that mimics human bone marrow to produce human platelets. Platelets are the 'band-aids' of the bloodstream, responsible for clot formation and blood vessel repair. Over 2 million platelet transfusions are administered annually, which dramatically increase survival rates for cancer, transplant, and surgery patients. For various reasons donor-platelets are both risky and limited. Creating a safer and unlimited alternative allows us to fundamentally disrupt a $1.7B market.
BB, totally agree, BTX's 600+ patents, 7 subsidiaries, no debt, research/therapeutics products is screaming BUY ME!
Our cancer ip rivals that of Merck, and Pfizer!
The first of seven subsidiaries will IPO shortly after announcing the the restart of Geron spine trials. Gonna be good!
No where to go but up!
Two low hanging fruit products:
Cancer diagnostic product Panc-DX and Renevia(adipose cell/ECM derived plastic surgery product). Both products due out on the market within 6 months! BUY-BUY-BUY!
More proof Biotimes extra-cellular matrix is a winner! Very important since our regen devices are all based on HyStem.
BTX also licensing Cornell's vascular stem cell ip, use for this ip will also be combined with our acquired Cell Targeting nano-peptide tumor destroying ip. Announcements of our revolutionary cancer therapy product clinical trials will also take place at many top hospitals including Cornell.
The Scientist » News & Opinion » Daily News
SCNT Picks Up Steam
Study confirms that somatic cell nuclear transfer, an alternate method of creating patient-specific pluripotent stem cells, can be used to reprogram adult cells.
Scientists at the New York Stem Cell Foundation (NYSCF) Research Institute, along with their international colleagues, have produced human embryonic stem cells (hESCs) by transferring the nuclei of skin cells from a 32-year-old type 1 diabetic woman into human eggs whose own nuclei had been removed, according to a study published today (April 28) in Nature. The researchers induced the hESCs to differentiate into insulin-secreting cells. They hope to eventually replace cells that type 1 diabetes patients lack with patient-specific insulin-secreting cells.
The publication comes hot on the heels of a study published earlier this month (April 17) in Cell Stem Cell that also showed the technique, called somatic cell nuclear transfer (SCNT), could be used on adult cells.
“This is the first report describing diploid patient-specific stem cell lines after somatic cell nuclear transfer, and together with the report that appeared . . . in Cell Stem Cell, it is also the first report on the derivation of diploid pluripotent stem cell lines from cells of an adult and from a human being after birth in general,” study coauthor Dieter Egli, a senior research fellow at the NYSCF, said during a press conference.
“This is an important demonstration that SCNT works and can be used to model and perhaps one day treat disease,” George Daley, a stem cell biologist at the Harvard Stem Cell Institute, Children’s Hospital Boston, and the Dana-Farber Cancer Institute, wrote in an e-mail to The Scientist. Daley was not involved in the research.
SCNT is a cellular-reprogramming alternative, and its products could have advantages over induced pluripotent s
9 MIL cash, 2 MIL debt, a ECM scaffold but no stem cells and hasn't even started trials....my money is with BTX.